Research work in the IBD outpatient clinic

• Phase 2

M20-371 - ABV154 -  Recruitment is ongoing

.

• Phase 3 und 3b

RPC01-3202 - Ozanimod - Induction - Recruitment is ongoing

.

RPC01-3203 - Ozanimod - Maintenance 

.

RPC01-3204 - Ozanimod - OLE

.

GS-US-419-3895 - Filgotinib - Induction and Maintenance - Recruitment is ongoing

.

GS-US-419-3896 - Filgotinib - LTE

.

CNTO1959CRD3001 - Guselkumab 

.

M16-000 - Risankizumab - Maintenance and OLE 

.

16T-MC-AMAM - Mirikizumab 

.

I6T-MC-AMAX - Mirikizumab - LTE

• Phase 2 und 2b:

ABX464-104 - ABX464 - OLE

.

CNTO1959UCO3001 - Guselkumab

.

• Phase 3

GS-US-418-3899 - Filgotinib - LTE

.

I6T-MC-AMAP - Mirikizumab - OLE

.

CNTO1959UCO3001 - Guselkumab 

A multicenter, randomized study to evaluate the clinical use of novel molecular markers in the therapy of patients with inflammatory bowel disease (IBD). At the Clinic for Internal Medicine I (Kiel), a research project on molecular medicine in the therapy of chronic inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis is being carried out. This is done in cooperation with the University Hospital Hamburg-Eppendorf, the Hannover Medical School, the Institute for Clinical Molecular Biology (IKMB), the Institute for Medical Informatics and Statistics (IMIS) and the Dr. Margerete Fischer-Bosch Institute for Clinical Pharmacology (Stuttgart). Novel biomarkers could help to control the drug treatment of patients with chronic inflammatory diseases more precisely and thus achieve more sustainable therapeutic success. In GUIDE-IBD, a project funded by the Federal Ministry of Education and Research (BMBF), we would like to include exactly these biomarkers for the first time in the context of biological therapy for IBD by analyzing your therapy with infliximab. The aim is to investigate whether the use of additional knowledge about the course of the disease through innovative biomarkers can help doctors to make better therapy decisions.

With the "SIGMOID" study, we plan to identify novel, predictive biomarkers regarding therapy response in patients with inflammatory bowel disease (IBD) under different therapy regimens. In the future, this should be able to guide individualized, optimized therapy regimes in IBD patient care and thus personalize and improve patient care globally. For this purpose, among other things, the application of innovative analysis techniques is carried out together with the working group of Prof. Yang Li at the Center for Individualized Infection Medicine (CiiM).

This study is funded by the German Research Society (DFG) as part of the Clinician Scientist Program PRACTIS.

If you are interested, please contact us at any time.

Principal Investigator: Dr. med. Miriam Wiestler